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Objective To evaluate the safety of CSL’s split-virion inactivated
trivalent 2009 Southern Hemisphere formulation influenza vaccine
(TIV) in children.
Methods We enrolled 1992 healthy children into three groups:
Cohorts A,  6 months to <3 years; B,  3 years to <9 years; and
C,  9 years to <18 years. Children received one or two doses of
025 ml (225 lg haemagglutinin) or 05 ml (45 lg) TIV,
depending on age and prior vaccination history. We collected post-
vaccination solicited adverse event (AE) data (days 0–6), including
fever (temperature:  375°C axilla,  380°C oral), unsolicited AEs
(days 0–29) and serious AEs (SAEs) and new-onset chronic illnesses
(NOCIs; to day 180 after last vaccination).
Results At least one solicited AE was reported by 80%/78%/78% of
children in Cohorts A, B and C, respectively. Systemic AEs were
more common among Cohort A (72% of participants), and local
AEs were more common among Cohort C (71% of participants).
Fever was more common in younger cohorts, in influenza vaccine-
na€ıve children (29% of Cohort A receiving their first dose), and
following first compared with second doses. Severe fever following a
first dose prevented 20 participants receiving their second scheduled
vaccine dose. A 7-month-old participant had a single uncomplicated
febrile convulsion on the day of vaccination.
Conclusions Nearly 80% of subjects reported at least one solicited
AE following immunization. Fever prevalence was highest in
vaccine-na€ıve Cohort A participants, similar to other paediatric
studies using CSL vaccine. Further research to understand fever-
related AEs in children following CSL’s TIV is recommended.
Keywords Adverse events, fever, influenza vaccine, paediatrics,
safety.
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Introduction
Influenza is a serious public health problem predictably
causing annual epidemics of infection, hospitalization,
economic burden and deaths. Children have the highest
rates of infection, have the highest rates of hospitalization
due to laboratory-confirmed influenza and are the principal
agents of transmission in communities.1–4 Annual vaccina-
tion is the most effective method for preventing influenza
and its complications. Influenza vaccines have been used in
adult populations for many decades, but the focus on their
use in children, for direct5,6 and indirect protection,4,7–12 is a
more recent phenomenon. This focus has led to a number of
recommendations for universal annual vaccination in healthy
children.13,14 Following a cluster of three paediatric deaths in
Western Australia (WA) during 2007, a State Government
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influenza vaccination programme was established for chil-
dren aged  6 months to <5 years from 2008, with free
vaccine provided by the WA Government in conjunction
with CSL Biotherapies and Sanofi Pasteur.15 Seasonal influ-
enza vaccine has been recommended for Australians
 6 months of age with medical conditions predisposing
to severe influenza for many years, and this became publicly
funded nationally for this cohort in 2010.16
There is a relative lack of published safety information on
the use of influenza vaccines in children, particularly for
younger cohorts.17 At the time of this study, there was one
published study reporting safety data for CSL’s seasonal
trivalent split-virion inactivated influenza vaccine (Fluvax;
CSL Ltd, Parkville, Vic., Australia) in children.18 A US
controlled trial was also commenced during the conduct of
this study, with results now available at ClinicalTrials.gov
(Table 1).19 With this study, we sought to expand the
available safety data for the use of seasonal influenza vaccine
in children.
Methods
Study design
This prospective, multicentre, open-label, uncontrolled phase
IV clinical trial (ClinicalTrials.gov: NCT00825162) was
conducted at seven Australian sites during the 2009 Southern
Hemisphere autumn. The primary objective of the study was
to evaluate the safety and tolerability of the trivalent
inactivated influenza vaccine (Fluvax and Fluvax Junior;
CSL Limited) in infants, children and adolescents. The study
was conducted in accordance with the International Confer-
ence on Harmonization Guideline for Good Clinical Practice.
Table 1. Percentage (with 95% confidence intervals) of participants reporting fever* of any severity in the 7 days (day 0 to day 6) following
administration of CSL’s seasonal trivalent influenza vaccine, and one control comparator, by dose and age group
Study and vaccine Dose
Age cohorts
6 months to
<3 years
3 to <9 years
[ 3 to <5 years
/ 5 to <9 years] 9 to <18 years
Study: Nolan et al.18,**
2005 trivalent Southern Hemisphere vaccine 2005 n = 151 n = 147 n = 0***
Dose one 23 (17–31) 16 (11–23)
[23 (15–35)/10 (5–18)]
–
Dose two 23 (17–30) 8 (5–14)
[(17 (10–29)/1 (0–7)]
–
2006 trivalent Southern Hemisphere vaccine 2006 n = 76 n = 197 n = 0***
Single booster dose 39 (29–51) 27 (21–33)
[41 (32–50)/12 (7–21)]
–
Study: safety profile of CSL Limited’s influenza virus vaccine compared to a US licensed comparator influenza virus vaccine19
2009/2010 trivalent Northern Hemisphere vaccine n = 231 n = 254 n = 254
Dose one 37 (31–43) 22 (17–28)
[32 (23–43)/16 (11–22)]
6 (4–10)
Dose two 15 (11–20) 2 (1–5)
[14 (9–23)/0 (0–2)]
–†
Comparator split-virion vaccine (Fluzone) n = 228 n = 257 n = 250
Dose one 14 (10–19) 9 (6–13)
[11 (6–19)/9 (6–14)]
4 (2–7)
Dose two 14 (10–19) 2 (1–4)
[16 (10–25)/2 (1–5)]
–†
This study
2009 trivalent Southern Hemisphere vaccine n = 710 n = 880 n = 402
Dose one 29 (26–32) 19 (17–22)
[28 (24–33)/14 (11–17)]
5 (3–8)
Dose two 18 (15–21) 10 (8–12)
[13 (10–17)/7 (5–10)]
–†
*Fever defined as temperature measured 375°C (axillary) or  380°C (oral).
** 3 to <9 years Cohort18 divided into  3 to <5 years and  5 to <9 years for comparison to other study.19
***This age group not in study.
†Annual single dose only required in this age group.
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The study protocol was approved by the Human Research
Ethics Committee at each study centre, and written informed
consent was obtained from each participant’s parent/guard-
ian prior to any study procedures. Participant assent was also
obtained from those capable of making an informed decision
about their own participation, in accordance with local
institutional ethics committee guidelines.
Study participants
Healthy children aged  6 months to <18 years were eligible
to participate. Exclusion criteria included an allergy to egg
products or any vaccine component; evidence of an active
infection; receipt of an experimental or seasonal influenza
vaccine in the previous 6 months; a confirmed or suspected
immunosuppressive condition; a history of Guillain–Barre
syndrome; a major congenital defect or serious illness; a
history of neurologic disorders or seizures (single seizure
events more than 2 years previously permitted); receipt of
immunoglobulins or blood products within the previous
3 months; participation in a clinical study or use of an
investigational compound within the previous 3 months;
receipt of recent immunosuppressive and immunomodula-
tory medication, including systemic corticosteroids; and
treatment with cytotoxic drugs. Children aged  6 months
to <9 years had to be born at or after 36 weeks of gestation
to be eligible for enrolment, and adolescent females
 9 years of age were required to provide a negative
pregnancy test prior to vaccination.
Participants were stratified into three cohorts based on age
at time of enrolment with number of doses and volume
(025/05 ml) determined by cohort and prior immunization
history (Table S1).
Study vaccine
The 2009 Southern Hemisphere trivalent inactivated influ-
enza vaccine was used, manufactured at CSL’s plant in
accordance with the registered procedure. Each 05 ml of
vaccine contained 15 lg of each of the following haemag-
glutinin antigens: A/Brisbane/59/2007 (H1N1), A/Brisbane/
10/2007 (H3N2) and B/Florida/4/2006, as recommended by
the World Health Organization for the 2009 Southern
Hemisphere influenza season. The study vaccine virus was
propagated in the allantoic fluid of embryonated chicken
eggs. Following harvest of virus, the following steps were
used to produce a purified split-virion vaccine: purification
using a sucrose gradient, inactivation with b-propiolactone,
virus splitting using sodium taurodeoxycholate, purification
and suspension in a phosphate-buffered isotonic solution.
The vaccine is thiomersal free.
Study procedures
Study visits were conducted on days 0 (dose one), 30 + 4
(exit visit for single-dose participants or administration of
dose two), 60 + 4 (two-dose participants exit visit only),
with a final safety telephone contact at 180 + 14 days
following the last vaccine dose. A medical examination was
performed during visits, and a 30-minutes observation
period followed vaccination.
Parents used diary cards to record solicited local and
systemic AEs on the day of vaccination and during the
6 days following (Table S2); unsolicited AEs and any
medications taken on the day of vaccination and during
the 29 days following; and medication used to treat and
medical visits for an AE. The occurrence of serious AEs
(SAEs) and new-onset chronic illnesses (NOCIs) was
assessed up to 180 days following the last vaccine dose.
An SAE was any untoward medical occurrence resulting in
death, which was life-threatening, required an unexpected
inpatient hospitalization (at least 24 hours) or prolonga-
tion (by at least 24 hours) of existing hospitalization;
resulted in persistent or significant disability/incapacity;
was a congenital anomaly/birth defect; and/or was judged
by the treating physician to be medically significant.
Adverse event severity was graded as mild (Grade 1),
moderate (Grade 2) or severe (Grade 3), following parent
training (Table S2).
All solicited local AEs were considered related to the study
vaccine. Clinical significance and causality of solicited
systemic AEs, all unsolicited AEs and NOCIs were assigned
by the site investigator.
A severe fever (Table S2)  400°C (oral) or  395°C
(axillary) within 48 hours of vaccination was one of the
contraindications to administering further doses of study
vaccine. Oral and axillary temperatures are presented as
combined data.
Statistical analyses and power
The number and proportion (with 95% confidence intervals)
of participants with an AE following dose one and dose two
are summarized using a safety population comprising all
participants who received the relevant dose and provided at
least one safety assessment after vaccination.
We planned for a safety population of 2025 participants:
Cohort A, 810 participants; Cohort B, 810; and Cohort C,
405. Based on expected enrolment, AEs occurring at a rate of
1 in 1000 participants had an 868% probability of being
detected, and AEs with rates of 1 in 676 had a 95% chance of
being observed.
Results
Participants
Informed consent was provided for 2024 potential partic-
ipants, and of these, 1992 were enrolled and stratified by age:
Cohort A, 710 members; Cohort B, 880 members; and
Cohort C, 402 members (Tables 2 and S1, Figure 1).
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Despite considerable efforts during the available enrolment
window prior to the commencement of the local influenza
season, fewer Cohort A participants were enrolled than
planned; but numbers were felt sufficient to still enable
meaningful analysis of the safety data. Within the enrolled
cohorts (A/B/C), AEs occurring at a rate of 1 in 300 had a
907/947/739% chance of detection and AEs with a rate of
1 in 238/294/135 had a 95% chance of being observed,
respectively.
The first subject was vaccinated on 6 March 2009, the final
dose one was given on 16 July 2009, the final dose two on 24
August 2009, and the final day 180 telephone call was made
on 22 February 2010. The first Australian case of influenza A
(H1N1)pdm09 virus was confirmed in Brisbane on 9 May
2009,20 and virus circulation became rapidly widespread in
all site cities.21
A total of 55 participants withdrew (Figure 1) from the
study (Cohort A: 28; Cohort B: 21; and Cohort C: 6). A
further 17 subjects (Cohort A: 10 and Cohort B: 7) were
initially classified as withdrawn, but went on to provide final
safety data at the day 180 telephone contact – therefore, not
meeting the study definition of a withdrawn subject. These
17 subjects had AEs following dose one: fever (axillary
temperature  395°C within 48 hours of vaccination,
n = 15), influenza-like illness (n = 1) and urticarial rash
(n = 1). The 15 participants with a severe fever AE following
dose one were part of a larger group of 20 participants
(Figure 1) who did not receive a scheduled dose two due to a
severe fever AE following dose 1 (Cohort A: 13 and Cohort B:
7). These 20 subjects did not meet the definition of a
withdrawn subject as they provided ongoing safety data until
study conclusion.
Thirteen percent of participants had received influenza
vaccine during the 2008 season, and 13% had received
vaccine at any time prior to 2008.
Safety and tolerability
Solicited local adverse events
Solicited local AEs were common (Table 3) and were mostly
of mild/moderate severity (Table 4) and short-lived. Solic-
ited local AEs were more common in older children and
decreased within cohorts following dose two: reported by
361%, 585% and 706% of participants in Cohorts A, B and
C, respectively, after the first vaccination, and 272% and
492% of participants in Cohorts A and B, respectively,
following dose two (Table 4). Injection site pain was the
most commonly reported local AE in all cohorts.
Solicited systemic adverse events
The frequency of solicited systemic AEs (Table 4) following
dose one was highest in Cohort A (603%), was similar in
Cohorts C (427%) and B (395%) and fell with a second
dose in both Cohorts A (424%) and B (248%).
Fever was more common in the younger cohorts, in those
who had not previously received any influenza vaccine and in
those receiving a first study dose compared with those
receiving the second study dose (Table 4).
To allow comparison with data from other studies, Cohort
B was divided into children aged  3 to <5 and children aged
 5 and <9 years (Table 1). Fever of severe intensity
following dose 1 was reported by 13 participants in Cohort
A (18%) and seven participants in Cohort B (08%),
including a 7-month-old participant (Cohort A) who had a
febrile convulsion within 4 hours of receiving dose one. This
participant experienced fever of 399°C (axilla) and severe
vomiting on the day of and the day following dose one. She
was seen in a hospital emergency department, but not
admitted, and treated with paracetamol, ibuprofen and oral
rehydration solution. The fever and vomiting had concluded
on the day following vaccination.
There were 588 episodes of fever of any intensity following
vaccination: 389 (66%) of Grade 1 fever, 171 (29%) of Grade
2 and 28 (4%) of Grade 3 (Table 5). When fever did occur, it
was managed using antipyretics on 57% of occasions, and
resulted in a healthcare visit on 14% of occasions. Details on
the duration of fever by grade, antipyretic treatment and
healthcare use in response to fever are provided (Table 5).
Of the 392 fever episodes of any intensity reported on the
day of or the 6 days following dose 1, fever commenced on
the same day as vaccination in 178 (45%) and on the next
day in 143 (36%). For the 173 fever episodes following dose
2, the equivalent values are 55 (32%) and 29 (17%),
respectively.
Unsolicited adverse events
There were no deaths in study participants (Table 3). Of 26
SAEs, none were assessed as causally related to vaccine by
investigators. Seventeen subjects reported 20 NOCIs; two
Table 2. Participant characteristics
Characteristics
Cohort A
(n = 710)
Cohort B
(n = 880)
Cohort C
(n = 402)
Mean age, years
(standard deviation)
184 (074) 554 (166) 1264 (248)
Female sex, n (%) 458 (325) 499 (439) 502 (202)
Previous receipt of
any influenza
vaccination, n (%)
100 (71) 295 (260) 226 (91)
Receipt of influenza
vaccine prior to
2008, n (%)
32 (23) 201 (177) 162 (65)
Receipt of influenza
vaccine during
2008, n (%)
86 (61) 174 (153) 134 (54)
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were considered possibly vaccine-related by investigators:
food allergy and eczema.
Unsolicited AEs were common, reported by 617% of total
participants: Cohort A: 755% of participants; Cohort B:
595%; and Cohort C: 420% (Table 3).
In each cohort, the most common unsolicited AE was
upper respiratory tract infection (Cohort A: 296%; Cohort
B: 162%; and Cohort C: 83%). As there was no viral
testing conducted during respiratory tract illness in this
study, it is not possible to report association of these
illnesses with influenza A(H1N1)pdm09 or other respiratory
viruses.
Discussion
In this study of CSL’s 2009 Southern Hemisphere TIV, we
found AEs to be common, with 59% of children having at
least one solicited local AE and 55% of children having at
least one solicited systemic AE following immunization.
Most AEs were graded as mild or moderate in severity, with
Grade 3 AEs uncommon. Twenty participants in Cohorts A
and B did not receive a scheduled second dose of study
vaccine as per protocol due to Grade 3 fever following dose
one, with one-7-month-old experiencing a single febrile
convulsion on the day of vaccine administration. When
Excluded (n = 32)
Not meeting inclusion criteria (n = 28)
Declined to participate (n = 2)
Other reasons (n =  2)
Assessed for eligibility (n = 2024)
Enrolled participants, received dose 1 (n = 1992)
Cohort A (n = 710)
≥6 months to <3 years
Cohort B (n = 880)
≥3 years to <9 years
Cohort C (n = 402)
≥9 years to <18 years
Dose 1 safety cohort (n = 703)
No safety data provided (n = 7)
Dose 1 safety cohort (n = 875)
No safety data provided (n = 5)
Dose 1 safety cohort (n = 398)
No safety data provided (n = 4)
Eligible for dose 2 (n = 650)
Received dose 2 (n = 632)
Severe fever after dose 1 (n = 7)
Unavailable for study visit (n = 3)
Withdrew consent (n = 7)
Refused dose 2 (n = 1)
Not eligible for dose 2 but 
received dose 2 in error (n = 2)
Not eligible for dose 2 but 
received dose 2 in error (n = 1)
Dose 2 safety cohort (n = 615)
No safety data provided (n = 2)
Dose 2 safety cohort (n = 634) Dose 2 safety cohort (n = 1)
Eligible for dose 2 (n = 651)
Received dose 2 (n = 617)
Severe fever after dose 1 (n = 13)
Adverse event other than fever (n = 1)
Unavailable for study visit (n = 14)
Withdrew consent (n = 4)
Refused dose 2 (n = 1)
No reason offered (n = 1)
Eligible for dose 2 (n = 0)
Completed study (n = 859)
Withdrew from the study:
Withdrew consent (n = 13)
Lost to follow-up (n = 6)
Unable to attend study visit (n = 2)
Completed study (n = 682)
Withdrew from the study:
Withdrew consent (n = 11)
Moved from study area (n = 1)
Lost to follow-up (n = 9)
Investigator decision (n = 2)
Unable to attend study visit (n = 5)
Completed study (n = 396)
Withdrew from the study:
Withdrew consent (n = 3)
Lost to follow-up (n = 3)
Figure 1. Study design and participant designation.
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present, fever typically began shortly after immunization: in
82% of those who reported fever following dose 1, it
commenced on the same or day following vaccination; and in
49% for dose 2. Two NOCIs were considered possibly
vaccine-related (food allergy and eczema): neither is listed as
a possible AE in the product information, and there is no
clear causal association between TIV and these AEs.
We report our findings in the context of an increased focus
on the safety, particularly fever-related AEs, of CSL’s trivalent
seasonal influenza vaccine in children.22 CSL’s 2010 Southern
Hemisphere trivalent influenza vaccine was associated with
the rapid onset of fever in children, with febrile convulsions
in some. Results from this study were provided to the
Australian Government by CSL Limited to assist with the
initial safety review of the 2010 events. From this study,
severe and any graded, fever was highest in vaccine-na€ıve
children in the youngest cohort, providing some confidence
that the severe fever AEs seen in 2010 were unlikely to be due
to repeated annual doses of CSL’s seasonal TIV vaccine.
In subsequent findings from the WA programme, those
aged 6–59 months who received CSL’s 2010 TIV had a fever
prevalence of 565%, compared with 173% in children
receiving another brand of TIV, as reported retrospectively
by their parents most likely blinded to vaccine brand.22
Further, in the 49 days following WA programme com-
mencement in 2010, 38 febrile convulsions were identified as
occurring within 72 hours of vaccine administration.22
Despite the prevalence of fever AEs associated with CSL’s
2009 TIV in this study, the rate of febrile convulsions
following administration of CSL TIV in young children
reported from WA was significantly lower in 2009 and 2008,
when compared to 2010.22 The prevalence estimates for
febrile convulsions following administration of the CSL
Southern Hemisphere 2010 preparation range from a con-
servatively estimated value for all children <5 years of age 81
per 1000 doses (Fluvax Junior),22 to approximately one in
100.23
The proportion of participants reporting any fever in this
study fell within the range reported in the two studies (one
reported on ClinicalTrials.gov) with safety data available for
CSL’s TIV in children (Table 1).18,19 Fever following dose
one/two for Cohort A (29%/18%) and Cohort B (20%/10%)
was somewhat higher for dose one compared to the 2005
Southern Hemisphere formulation: Cohort A (23%/23%)
and Cohort B (16%/8%), but lower than the values for the
single dose of 2006 Southern Hemisphere formulation:
Cohort A (39%) and Cohort B (27%).18 Dose one values
were lower than the 2009/2010 Northern Hemisphere
Table 3. Summary of adverse events (AE) and fever-related events in the safety populations after first/second dose of vaccine
AEs in study safety cohorts
Cohort A (n = 703)
% (n)
Cohort B (n = 875)
% (n)
Cohort C (n = 398)
% (n)
Total (n = 1976)
% (n)
One or more AEs 915 (643) 877 (767) 847 (337) 884 (1747)
Eligible but did not receive dose two
due to AE
18 (13) 08 (7) 0 10 (20)
Solicited AEs* 801 (563) 782 (684) 779 (310) 788 (1557)
Any solicited local AEs 434 (305) 669 (585) 706 (281) 593 (1171)
Any solicited systemic AEs 717 (504) 466 (408) 427 (170) 548 (1082)
Unsolicited AEs** 755 (531) 595 (521) 420 (167) 617 (1219)
Deaths 0 0 0 0
Serious AEs (SAEs) 27 (19) 06 (5) 05 (2) 13 (26)
SAEs considered related to vaccine*** 0 0 0 0
Withdrawal due to an SAE 0 0 0 0
New-onset chronic illnesses (NOCIs)† 14 (10) 06 (5) 05 (2) 09 (17)
NOCIs considered related to vaccine*** 03 (2) 0 0 01 (2)
Fever-related events
Subject unable to receive prescribed
dose 2 due to severe fever AE following
dose 1
18 (13) 08 (7) –†† 15 (20)†††
Febrile convulsion following immunization 01 (1) 0 0 01 (1)
*Solicited AEs from day 0 to day 6 following vaccine.
**Unsolicited AEs include: unsolicited AEs from day 0 to day 29 following vaccine and SAEs/NOCIs from day 0 to day 180 following the last dose of
vaccine.
***Related AEs are those assessed by an investigator as having a causality of unknown, possibly, probably or definitely related to study vaccine.
†Three Cohort A children each had two NOCI events, meaning a total of 20 NOCIs were reported in 17 children.
††Second dose not given to Cohort C.
†††Denominator: Cohort A and Cohort B subjects eligible for dose 2 (n = 1301).
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formulation in Cohort A (dose one/two: 37%/15%), but
similar for Cohorts B (22%/2%) and C (6%/–) (Tables 1 and
4).19 From that same study, dose one values for the control
split-virion vaccine were consistently lower than any of the
CSL preparations, including the one used in this study
(Table 1).19 Fever was also more common with the 30 lg
(double) dose of CSL’s 2009 monovalent influenza A(H1N1)
vaccine: in an uncontrolled Australian study, for all partic-
ipants ( 6 months to <9 years) following dose one any
fever occurred in 24% (15 lg haemagglutinin) and 41%
(30 lg) of recipients, and following dose two, 18% and 14%,
respectively.24 From a placebo-controlled US study using the
same product, the proportion of participants with any fever
in Cohort A ( 6 months to <3 years) following dose one or
two was 23% (placebo arm), 25% (75 lg) and 43% (15 lg),
for Cohort B ( 3 to <9 years) 14% (placebo), 19% (75 lg)
and 20% (15 lg).25
Whilst there is no definitive explanation for the increased
reactogenicity of CSL’s 2010 Southern Hemisphere TIV, or
CSL’s other seasonal TIVs, a number of potential causes
have been put forward.26 One possible contributing factor,
inadequate splitting of vaccine virions by sodium taur-
odeoxycholate, may be intermittent.27 Analyses conducted
by Blyth et al.28 as well as by CSL29 indicate that the CSL
TIVs, as a class, generally induce higher levels of cytokines
in in vitro paediatric peripheral blood mononuclear cells
(PBMCs) and whole blood cell assays, and that this resulted
from a viral-derived, heat-labile component, and not
bacterial contamination.29 Based on current information,
it is thought that increased AEs seen in children receiving
CSL’s 2010 Southern Hemisphere TIV resulted from the
combination of differences in the method of manufacture of
the CSL TIVs, as compared to other TIV manufacturers,
and the effect of the newly introduced H1N1 strain
combined with the particular B strain recommended that
season.29
As a result of the higher than expected rates of febrile
convulsions in children receiving CSL’s 2010 Southern
Hemisphere TIV, CSL TIVs are not currently approved for
use in children <5 years of age and not recommended for
children aged 5 to <10 years in Australia if alternative
vaccines are available.
In this study using CSL’s 2009 Southern Hemisphere TIV,
we found fever was more common than a 2009/2010
Table 4. Any and Grade 3 solicited local and systemic adverse events (AE) within 6 days after administration of study vaccine
AE
Cohort A
% (n)
Cohort B
% (n) Cohort C
% (n)
Dose 1 Dose 2 Dose 1 Dose 2 Dose 1
Any local solicited AE 361 (254) 272 (167) 585 (512) 492 (312) 706 (281)
Any Grade 3 event 06 (4) 05 (3) 35 (31) 21 (13) 38 (15)
Pain 228 (160) 180 (111) 529 (463) 445 (282) 681 (271)
Grade 3 01 (1) 03 (2) 02 (2) 03 (2) 03 (1)
Redness (erythema) 221 (148) 177 (109) 216 (189) 172 (109) 166 (66)
Grade 3 03 (2) 02 (1) 21 (18) 11 (7) 20 (8)
Injection site swelling (induration) or lump 94 (66) 104 (64) 157 (137) 121 (77) 131 (52)
Grade 3 03 (2) 0 22 (19) 13 (8) 30 (12)
Any systemic solicited AE 603 (424) 424 (261) 395 (346) 248 (157) 427 (170)
Any Grade 3 event 57 (40) 23 (14) 27 (24) 21 (13) 10 (4)
Fever 286 (201) 179 (110) 195 (171) 99 (63) 50 (20)
Grade 3 18 (13) 10 (6) 08 (7) 03 (2) 0
Headache 36 (25) 20 (12) 155 (136) 60 (38) 269 (107)
Grade 3 01 (1) 0 05 (4) 06 (4) 05 (2)
Myalgia 37 (26) 26 (16) 99 (87) 54 (34) 201 (80)
Grade 3 3 (04) 02 (1) 3 (03) 05 (3) 0
Nausea/vomiting 112 (79) 50 (31) 86 (75) 39 (25) 53 (21)
Grade 3 17 (12) 07 (4) 07 (6) 08 (5) 03 (1)
Diarrhoea 142 (100) 85 (52) 46 (40) 32 (20) 53 (21)
Grade 3 06 (4) 05 (3) 02 (2) 0 03 (1)
Loss of appetite (Cohort A only) 201 (141) 133 (82) – – –
Grade 3 11 (8) 07 (4) – – –
Irritability (Cohort A only) 420 (295) 285 (175) – – –
Grade 3 34 (24) 11 (7) – – –
Malaise (Cohorts B and C only) – – 205 (179) 114 (72) 166 (66)
Grade 3 – – 16 (14) 16 (10) 03 (1)
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Northern Hemisphere split-virion comparator in a US study,
as described in data available on ClinicalTrials.gov.19 Further
work continues on attempting to identify the issue or issues
responsible for the increased reactogenicity of CSL’s TIV in
children.
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